for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akers Biosciences Inc

AKER.OQ

Latest Trade

0.42USD

Change

0.01(+2.49%)

Volume

13,085

Today's Range

0.40

 - 

0.43

52 Week Range

0.39

 - 

3.92

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.41
Open
0.40
Volume
13,085
3M AVG Volume
3.36
Today's High
0.43
Today's Low
0.40
52 Week High
3.92
52 Week Low
0.39
Shares Out (MIL)
12.51
Market Cap (MIL)
5.01
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2019 Akers Biosciences Inc Earnings Release

Latest Developments

More

Akers Biosciences Reports Q2 2019 Earnings

Akers Biosciences Reports Q1 Operating Loss Of $0.9 Mln

Akers Biosciences - Anticipated That Trading In Common Stock On Aim Will Cease, Delisting Will Take Effect, From 7.00 A.M. (Gmt) On March 29

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Akers Biosciences Inc

Akers Biosciences, Inc. develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company's product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives. The Company's primary focus is the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company's main products include a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body.

Industry

Biotechnology & Drugs

Contact Info

201 Grove Rd

+1.856.8488698

http://www.akersbio.com

Executive Leadership

Howard R. Yeaton

Chief Executive Officer, Interim Chief Financial Officer

Christopher C Schreiber

Independent Director

Joshua N. Silverman

Independent Director

Bill Joe White

Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
2.62
Price To Book (MRQ)
1.16
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-114.28
Return on Equity (TTM)
-92.94

Latest News

Latest News

BRIEF-Akers Biosciences Files Non Timely 10-Q - SEC Filing

* AKERS BIOSCIENCES INC FILES NON TIMELY 10-Q - SEC FILING Source text: (https://bit.ly/2k6a2jr) Further company coverage:

BRIEF-Akers Biosciences Says Terminated Raymond Akers Positions As Executive Chairman

* SAYS TERMINATED RAYMOND AKERS POSITIONS AS EXECUTIVE CHAIRMAN, CHIEF SCIENTIFIC DIRECTOR AND SECRETARY OF COMPANY

BRIEF-Akers Biosciences Says Appointed Richard Carlyle Tarbox III As Interim Non-Executive Chairman

* AKERS BIOSCIENCES - BOARD TERMINATED RAYMOND AKERS FROM POSITION AS EXECUTIVE CHAIRMAN OF BOARD, CHIEF SCIENTIFIC DIRECTOR AND SECRETARY OF COMPANY

BRIEF-Akers Biosciences Expands Outsourced U.S. Distribution Capabilities For Heparin PF4 Rapid Test

* AKERS BIOSCIENCES EXPANDS OUTSOURCED US DISTRIBUTION CAPABILITIES FOR HEPARIN PF4 RAPID TEST

BRIEF-Akers Biosciences Reports Earnings For Fiscal Year 2017

* AKERS BIOSCIENCES REPORTS EARNINGS FOR FISCAL YEAR 2017 Source text for Eikon: Further company coverage:

BRIEF-Akers Biosciences Signs Distribution Agreement With Diagnostica Stago

* AKERS BIOSCIENCES SIGNS US DISTRIBUTION AGREEMENT WITH DIAGNOSTICA STAGO

BRIEF-Akers Biosciences Announces Distribution Agreement With Diagnostica Stago​

* ENTERED INTO 3-YEAR DISTRIBUTION AGREEMENT WITH DIAGNOSTICA STAGO FOR SALE OF CO'S RAPID TEST FOR HEPARIN-INDUCED THROMBOCYTOPENIA ACROSS US Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Alpha Capital Anstalt Reports 9.9 Pct Passive Stake In Akers Biosciences

* ALPHA CAPITAL ANSTALT REPORTS 9.9 PERCENT PASSIVE STAKE IN AKERS BIOSCIENCES INC AS ON DECEMBER 21 - SEC FILING Source text (http://bit.ly/2BZ9Q04) Further company coverage:

BRIEF-Akers Biosciences - Accutest Solutions secured new channel partner for sales​

* Akers Biosciences - announces Accutest Solutions a distributor of Akers Bio's breathscan alcohol detector in UK, secured new channel partner for sales

BRIEF-Akers Biosciences Inc Q2 revenue up 25 pct

* Qtrly loss before income tax reduced by 34% to $666,647 Source text for Eikon: Further company coverage:

BRIEF-Akers Biosciences Q2 revenue $1.2 million

* Q2 revenue $1.2 million Source text for Eikon: Further company coverage:

BRIEF-Akers Biosciences reports earnings for fiscal year 2016

* Akers Biosciences - Expect 2017 to be characterized by further growth in flagship PIFA Heparin PF/4 rapid assay product line, sales of rapid cholesterol test Source text for Eikon: Further company coverage:

BRIEF-Akers Biosciences to commercialize heparin PF4 rapid test in Puerto Rico

* Akers Biosciences to commercialize heparin PF4 rapid test in Puerto Rico Source text for Eikon: Further company coverage:

BRIEF-Empery Asset Management reports 8.45 pct passive stake in Akers Biosciences

* Empery Asset Management LP reports 8.45 percent passive stake in Akers Biosciences Inc, as of March 30, 2017 - sec filing Source text - http://bit.ly/2nTrng1 Further company coverage:

BRIEF-Akers Biosciences files for non-timely 10-K - SEC filing

* Akers Biosciences Inc files for non-timely 10-K - SEC filing

BRIEF-Akers Biosciences announces a $2 million private placement

* Akers Biosciences Inc - Akers Bio will issue 1.4 million shares at a price of $1.40 per share Source text for Eikon: Further company coverage:

BRIEF-Akers Biosciences begins selling rapid cholesterol test

* Akers Biosciences begins selling rapid cholesterol test through distribution agreement with first check Source text for Eikon: Further company coverage:

BRIEF-Akers Biosciences allowed U.S. patent for Akers Wellness tests cartridge

* US patent,trademark office allowed patent covering akers bio's proprietary cartridge for optical scanning device

BRIEF-Akers Biosciences prices 1.6 mln share offering at $1.20 per share

* Akers Biosciences announces pricing of public offering of 1,667,000 shares and 833,500 warrants

BRIEF-Akers Biosciences files for potential stock shelf, size not disclosed

* Files for potential stock shelf; size not disclosed - sec filing Source text : http://bit.ly/2fGeOku Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up